Aesthetic device company BTL Aesthetics has announced the launch of facial management device EMFUSION, debuting at CCR 2026.
According to BTL Aesthetics, EMFUSION is a non-invasive treatment that aims to support long-term skin health through restoration of the skin barrier. The company states that the treatment is designed to address skin ageing by focusing on skin function rather than solely on surface-level improvements.
BTL Aesthetics explains EMFUSION incorporates its DYNAM IQ technology, which aims to help rebalance and strengthen the epidermal barrier. The company claims that this may support the skin’s defence against environmental stressors and visible signs of ageing. According to BTL Aesthetics, EMFUSION can be used before other procedures, alongside combination treatment protocols or as part of ongoing maintenance programmes.
James Carr, BTL sales and marketing director, commented, “EMFUSION represents a landmark advancement in multi-layered in-clinic skin treatment. As the first treatment to utilise DYNAM IQ technology, EMFUSION is specifically designed to restore the skin barrier and help protect the skin against the visible signs of ageing, supporting long-term skin resilience and function.”